Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.
2.

Discovery and development of SAHA as an anticancer agent.

Marks PA.

Oncogene. 2007 Feb 26;26(9):1351-6. Review.

PMID:
17322921
3.

Development of vorinostat: current applications and future perspectives for cancer therapy.

Richon VM, Garcia-Vargas J, Hardwick JS.

Cancer Lett. 2009 Aug 8;280(2):201-10. doi: 10.1016/j.canlet.2009.01.002. Epub 2009 Jan 31. Review.

PMID:
19181442
4.
5.

Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.

Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, Aranda A.

Clin Transl Oncol. 2008 Jul;10(7):395-8. Review.

PMID:
18628067
6.

Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades N.

Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4072-9. doi: 10.1167/iovs.09-3517. Epub 2009 Apr 22.

PMID:
19387079
7.

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.

Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP.

Clin Cancer Res. 2007 Feb 1;13(3):1045-52.

8.

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.

Mol Cancer Ther. 2009 Jun;8(6):1596-605. doi: 10.1158/1535-7163.MCT-08-1004. Epub 2009 Jun 9.

9.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1060-6. Epub 2007 Oct 25.

10.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM.

Cancer Res. 2001 Dec 1;61(23):8492-7.

11.

Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.

Riester D, Hildmann C, Schwienhorst A.

Appl Microbiol Biotechnol. 2007 Jun;75(3):499-514. Epub 2007 Mar 22. Review.

PMID:
17377788
12.

Histone deacetylase inhibitors in cancer therapy.

Lane AA, Chabner BA.

J Clin Oncol. 2009 Nov 10;27(32):5459-68. doi: 10.1200/JCO.2009.22.1291. Epub 2009 Oct 13. Review.

PMID:
19826124
13.

Histone deacetylase inhibitors selectively suppress expression of HDAC7.

Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA.

Mol Cancer Ther. 2007 Sep;6(9):2525-34.

14.

Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.

Codd R, Braich N, Liu J, Soe CZ, Pakchung AA.

Int J Biochem Cell Biol. 2009 Apr;41(4):736-9. doi: 10.1016/j.biocel.2008.05.026. Epub 2008 Aug 3. Review.

PMID:
18725319
15.

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR.

Invest New Drugs. 2008 Feb;26(1):81-7. Epub 2007 Oct 25.

PMID:
17960324
16.

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK, Bonday Z, Goh KC, Hentze H, Hart S, Wang H, Ethirajulu K, Wood JM.

Mol Cancer Ther. 2010 Mar;9(3):642-52. doi: 10.1158/1535-7163.MCT-09-0689. Epub 2010 Mar 2.

17.
18.

Histone deacetylase inhibitors: molecular mechanisms of action.

Xu WS, Parmigiani RB, Marks PA.

Oncogene. 2007 Aug 13;26(37):5541-52. Review.

PMID:
17694093
19.
20.

Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.

Dong G, Wang L, Wang CY, Yang T, Kumar MV, Dong Z.

J Pharmacol Exp Ther. 2008 Jun;325(3):978-84. doi: 10.1124/jpet.108.137398. Epub 2008 Feb 29.

Items per page

Supplemental Content

Write to the Help Desk